A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

NCT ID: NCT05929807

Last Updated: 2025-10-27

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 140 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-21
• Study Completion Date: 2039-03-31

Brief Summary

TransCon CNP administered once-weekly in children and adolescents with achondroplasia who have completed a prior TransCon CNP clinical trial. Participants who complete a prior TransCon CNP trial and meet all eligibility criteria will be invited to continue into the long-term open label extension trial to receive 100 µg CNP/kg/week of TransCon CNP. Trial treatment will be completed when the participant reaches 16 years of age for females and 18 years of age for males and have femur and tibial epiphyseal closure. TransCon CNP treatment will continue if femur and tibial epiphyseal closure is not confirmed at the age of 16 years for females, and 18 years for males. Treatment with TransCon CNP will be completed once femur and tibial epiphyseal closure is confirmed by radiographic imaging. The trial duration is individual for each trial participant. Visits will occur every 12-14 weeks throughout the trial.

Conditions

Achondroplasia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TransCon CNP 100 mcg

TransCon CNP 100 mcg delivered once weekly by subcutaneous injection

Group Type: EXPERIMENTAL

TransCon CNP

Intervention Type: DRUG

TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Interventions

TransCon CNP

TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Written, signed informed consent of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC). For participants who are below the age of consent, a written assent will be obtained in accordance with applicable requirements as required by IRB/HREC/IEC. Upon reaching the legal age of consent, depending on applicable requirements, these participants will be asked to give their own written consent.
• Participants with achondroplasia who have completed a clinical trial with TransCon CNP.
• Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of TransCon CNP and to follow the protocol.
• Considered eligible based on the safety evaluations performed for evaluating stopping/holding rule criteria during the prior TransCon CNP clinical trial.

Exclusion Criteria

• Known or suspected hypersensitivity to the investigational product or related products (trehalose, tris[hydroxymethyl]aminomethane, succinate, and methoxy polyethylene glycol [mPEG]).
• Have received any dose of prescription medications, investigational medicinal product (other than TransCon CNP).
• Sexually active female participants and female partners of male participants of childbearing potential not using a highly effective form of contraceptive (including oral, injectable, or implantable contraception, or intrauterine device (IUD)) for the entire trial period and for 90 days post end of the trial.
• Participants with serum 25-hydroxy-vitamin D (25OHD) levels of <50 nmol/L (<20 ng/mL) at Visit 1 must be on treatment regimen of Vitamin D supplementation.
• Any disease or condition that, in the opinion of the investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This could include family situations, complications or manifestations, or medications that might impact safety or be considered confounding.

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 15 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ascendis Pharma Growth Disorders A/S

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Claus Strange

Role: STUDY_DIRECTOR

Ascendis Pharma A/S

Locations

Ascendis Pharma Investigational Site

Little Rock, Arkansas, United States

Ascendis Investigational Site

Aurora, Colorado, United States

Ascendis Investigational Site

Wilmington, Delaware, United States

Ascendis Investigational Site

Saint Paul, Minnesota, United States

Ascendis Pharma Investigational Site

Columbia Falls, Montana, United States

Ascendis Pharma Investigational Site

Buffalo, New York, United States

Ascendis Investigational Site

Houston, Texas, United States

Ascendis Pharma Investigational Site

Madison, Wisconsin, United States

Ascendis Pharma Investigational Site

Parkville, Victoria, Australia

Ascendis Investigational Site

Linz, , Austria

Ascendis Investigational Site

Montreal, , Canada

Ascendis Pharma Investigational Site

Copenhagen, , Denmark

Ascendis Investigational Site

Berlin, , Germany

Ascendis Pharma Investigational Site

Dublin, , Ireland

Ascendis Investigational Site

Auckland, , New Zealand

Ascendis Investigational Site

Coimbra, , Portugal

Ascendis Investigational Site

Vitoria-Gasteiz, , Spain

Countries

United States; Australia; Austria; Canada; Denmark; Germany; Ireland; New Zealand; Portugal; Spain

Other Identifiers

ASND0039

Identifier Type: -

Identifier Source: org_study_id